NIH extends agreement with Galapagos until end 2012

Galapagos NV (Euronext: GLPG) announced today that the U.S. National
Institutes of Health (NIH) have extended their agreement with Galapagos’
service division BioFocus for the operation of the Molecular Libraries
Small Molecule Repository (MLSMR) through December 2012. According to the
terms of this agreement, Galapagos will be eligible to receive up to $8.6
million (EUR7.0 million) over the course of the two year extension.

BioFocus runs a compound management facility for a number of industrial
and U.S. government customers out of its Compound Focus, Inc. subsidiary
in South San Francisco. Home to the MLSMR since 2004, this facility
acquires and stores compounds under the NIH contract and distributes
these compounds for high-throughput biological screening throughout the
NIH’s academic network in the U.S.

“We are pleased that the NIH has exercised its option to extend its
long-standing collaboration with BioFocus’ compound management facility
for another two years. BioFocus has proven that it consistently delivers a
high-quality service across the vast NIH screening center network,” said
Onno van de Stolpe, CEO of Galapagos.

About the Molecular Libraries Small Molecule Repository (a Roadmap
initiative)

The NIH MLSMR collects samples for high throughput biological screening
and distributes them to the NIH Molecular Libraries Screening Center
Network. MLSMR is a key component of the Molecular Libraries Initiative,
a NIH Roadmap project supporting ‘new pathways to discovery in the 21st
century’. The project is funded in whole with U.S. federal funds from the
National Institutes of Health, Department of Health and Human Services,
under contract HHS-N-278-2004- 41001C with Compound Focus, Inc.

About BioFocus

BioFocusaims to expand its partners’ drug pipelines by accelerating the
gene-to-drug candidate discovery process. This is achieved through a
comprehensive discovery platform, which includes target discovery in human
primary cells, focused as well as diverse compound libraries, in vitro and
cell-based screening, structural biology, medicinal chemistry, ADME/PK
services, supported by unique chemogenomic and informatics tools, and
compound library acquisition, storage and distribution services. As a
service division of Galapagos, BioFocus has over 250 employees based in
the UK, the US and Switzerland. More info at: www.biofocus.com

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and
antibody therapies with novel modes-of-action. The Company is progressing
one of the largest pipelines in biotech, with four clinical and over 50
small molecule discovery/pre-clinical programs. Through
risk/reward-sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen
Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to
receive EUR3.3 billion in downstream milestones, plus royalties. Together
with its BioFocus and Argenta service operations, Galapagos has over 670
employees and operates facilities in six countries, with global
headquarters in Mechelen, Belgium. More info at: www.glpg.com

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com

This release may contain forward-looking statements, including,
without limitation, statements containing the words “believes,”
“anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,”
“may,” “will,” “could,” “stands to,” and “continues,” as well as similar
expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause the
actual results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by
law or regulation.

[HUG#1430877]

This announcement
is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other
applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein. All reproduction for further
distribution is prohibited.

Source: Galapagos NV via Thomson Reuters ONE

Copyright 2010, Market Wire, All rights reserved.

Galapagos NV: NIH extends agreement with Galapagos until end 2012

Mechelen, Belgium; 12 July 2010 – Galapagos NV (Euronext: GLPG) announced today that the
U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos’
service division BioFocus for the operation of the Molecular Libraries Small Molecule
Repository (MLSMR) through December 2012. According to the terms of this agreement,
Galapagos will be eligible to receive up to $8.6 million (€7.0 million) over the course
of the two year extension.

BioFocus runs a compound management facility for a number of industrial and U.S.
government customers out of its Compound Focus, Inc. subsidiary in South San Francisco.
Home to the MLSMR since 2004, this facility acquires and stores compounds under the NIH
contract and distributes these compounds for high-throughput biological screening
throughout the NIH’s academic network in the U.S.

“We are pleased that the NIH has exercised its option to extend its long-standing
collaboration with BioFocus’ compound management facility for another two years.
BioFocus has proven that it consistently delivers a high-quality service across the vast
NIH screening center network,” said Onno van de Stolpe, CEO of Galapagos.

About the Molecular Libraries Small Molecule Repository (a Roadmap initiative)
The NIH MLSMR collects samples for high throughput biological screening and distributes
them to the NIH Molecular Libraries Screening Center Network. MLSMR is a key component
of the Molecular Libraries Initiative, a NIH Roadmap project supporting ‘new pathways to
discovery in the 21st century’. The project is funded in whole with U.S. federal funds
from the National Institutes of Health, Department of Health and Human Services, under
contract HHS-N-278-2004-41001C with Compound Focus, Inc.

About BioFocus
BioFocus http://www.biofocusdpi.com/ aims to expand its partners’ drug pipelines by
accelerating the gene-to-drug candidate discovery process. This is achieved through a
comprehensive discovery platform, which includes target discovery in human primary
cells, focused as well as diverse compound libraries, in vitro and cell-based screening,
structural biology, medicinal chemistry, ADME/PK services, supported by unique
chemogenomic and informatics tools, and compound library acquisition, storage and
distribution services. As a service division of Galapagos, BioFocus has over 250
employees based in the UK, the US and Switzerland. More info at: www.biofocus.com

http://www.biofocus.com/

About Galapagos
Galapagos http://www.glpg.com/ (Euronext: GLPG; OTC: GLPYY) is a mid-size
biotechnology company specialized in the discovery and development of small molecule and
antibody therapies with novel modes-of-action. The Company is progressing one of the
largest pipelines in biotech, with four clinical and over 50 small molecule
discovery/pre-clinical programs. Through risk/reward-sharing alliances with
GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier,
Galapagos is eligible to receive €3.3 billion in downstream milestones, plus royalties.
Together with its BioFocus and Argenta service operations, Galapagos has over 670
employees and operates facilities in six countries, with global headquarters in
Mechelen, Belgium. More info at: www.glpg.com
file://mars/ir/Press%20releases/2010/Apr/BioFocus%20CHDI/www.glpg.com

CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com mailto:ir@glpg.com

This release may contain forward-looking statements, including, without limitation,
statements containing the words “believes,” “anticipates,” “expects,” “intends,”
“plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as
well as similar expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause the actual results,
financial condition, performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results, financial conditions,
performance or achievements expressed or implied by such forward-looking statements.
Given these uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak only as of the date
of publication of this document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or circumstances on
which any such statement is based, unless required by law or regulation.

Open Identity Exchange Formed to Build Trust in Online Identity Management

Google, PayPal, Equifax, VeriSign, Verizon, CA, and Booz Allen Hamilton Sign
on to Board -
WASHINGTON & SAN FRANCISCO–(Business Wire)–
Industry leaders Google, PayPal, Equifax, VeriSign, Verizon, CA, and Booz Allen
Hamilton today announced at the RSA Conference 2010 the formation of the Open
Identity Exchange (OIX) www.openidentityexchange.org, a non-profit organization
dedicated to building trust in the exchange of online identity credentials
across public and private sectors. With initial grants from the OpenID (OIDF)
and Information Card Foundation (ICF), OIX has been approved as a trust
framework provider by the United States Government to certify online identity
management providers to U.S. federal standards for identity assurance.

Trust frameworks are a new way for one site to trust the identity, security, and
privacy assurances from another site (the “identity provider”) acting on behalf
of a user. Google, Paypal, and Equifax are the first three identity providers
certified by OIX to issue digital identity credentials that will be accepted for
privacy-protected registration and login at U.S. government websites. Verizon is
currently in the certification process and is expected to be completed shortly.

The National Institutes of Health (NIH) is the first government website
accepting these credentials, including OpenID and Information Card logins, a
capability it demonstrated today at the RSA Conference. Citizens can use open
identity technologies to support a number of online services across websites,
including customized library searches, access to training resources, conference
registration, and medical research wikis, with strong privacy protections, all
designed to ensure accessible and transparent communication between the
government agency and U.S. citizens.

“We want to acknowledge the critical role NIH has played as a pioneer in the
government`s use of open identity standards. The impact of the NIH iTrust pilots
is reflected not only in the formation of Open Identity Exchange in the
marketplace but also in the groundbreaking leadership NIH has demonstrated in
new public sector applications,” said Dr. Peter Alterman, Senior Advisor to the
NIH Chief Information Officer for Strategic Initiatives.

“OIX grew out of a public/private industry partnership initiated by the U.S.
government at this conference last year,” said Don Thibeau, OIDF Executive
Director and OIX Board Chair. “OpenID and Information Card technologies can
solve the technical problem of using identity credentials across different
websites, but can’t solve the problem of how those credentials can be trusted at
different levels of assurance. OIX is a solution to this problem not just for
the U.S. government, but for many different governments, industry alliances,
non-profit associations, telcos, academic networks, and others all over the
world who need to establish trust across a wide online population.”

The first official OIX trust framework meets the requirements set forth by the
U.S. Identity, Credential, and Access Management (ICAM) Trust Framework Provider
Adoption Process (TFPAP) established by the U.S. General Services Administration
(GSA). This trust framework will enable the American public to participate in
open, transparent and participatory government while maintaining full control of
how much or how little personal information they share with federal websites at
all times. “OIX means there is now a safe way to use an OpenID or an Information
Card to register and login at any number of federal websites without needing a
new username and password for each,” said Drummond Reed, ICF Executive Director
and Acting Executive Director of OIX. “As we roll out progressively stronger
levels of certification, this will empower U.S. citizens to access and mange
their tax records, Social Security records, veteran’s benefits, and many other
government services online.”

“Before organizations can confidently consume identity information produced by
third parties, they need to have confidence in those third parties’ business
processes and practices, and in the quality of the information they provide,”
said Bob Blakley, Research Director, Burton Group Identity and Privacy
Strategies, Gartner. “Before individuals can confidently provide information to
third parties, they need to have confidence that their privacy will be protected
by those third parties. The process of gaining confidence in a third party
organization’s processes for collecting, verifying, handling, using, and
disclosing identity information is called ‘identity assurance’. Identity
assurance is a key building block for the production and consumption of identity
information in open networks like the internet.”

OCLC Online Computer Library Center is another founding member of OIX because it
wants to develop a cooperative trust framework for libraries and their users.
“More than 72,000 libraries in 112 countries and territories around the world
have used OCLC services to locate, acquire, catalog, lend and preserve library
materials,” said Mike Teets, OCLC Vice President, Innovation. “An OCLC trust
framework could broaden online access to those library materials, and make it
easier for libraries to connect people to the knowledge they seek in any
format-digital or print.”

The OIX is currently working on development of trust frameworks for public
media, telecommunications, library services, state and local governments, and
professional associations. “We look forward to facilitating trusted transactions
throughout the government and eventually Internet channels,” said Thibeau. “True
trust requires the participation of a broad community so we are engaging
industry, government, legal and academia leaders in how best to resolve
challenges in usability, security and privacy.”

OIX Members and Industry Experts Discuss Open Trust Frameworks

“We’re pleased to be among the first organizations to be certified by the newly
created OIX,” said Eric Sachs, Senior Product Manager at Google. “We’ve already
seen encouraging implementations of identity technologies in the industry, and
our hope is that the work of the OIX will expand on this progress to help
facilitate more open government participation, as well as improve security on
the Internet by reducing password use across websites.”

“Trusted identities and consumer control of personal information are essential
to the effectiveness of transactions on the Internet,” said Andrew Nash, senior
director of identity services for PayPal Inc. “Trusted frameworks that provide
identity assurance are a critical factor in the success of the digital identity
ecosystem.”

“We are honored to support this critical initiative and work with thought
leaders of such a broad range of industry expertise,” said Ron Carpinella,
Equifax`s Vice President of Identity Management. “As an innovator of
knowledge-based authentication technology and the only information solutions
company on this board, we look forward to advancing the development of an open
trust platform initiative that will enable more secure and simplified
interaction between consumers and the digital world.”

“VeriSign is excited to participate in the next phase in the creation and
standardization of high assurance identity systems,” said Nicolas Popp, vice
president of product development at VeriSign. “Drawing from our experience in
bringing trust to the Internet, we look forward to contributing to the
development of a multichannel identity trust framework that will enable citizens
to communicate openly with confidence.”

“Verizon shares OIX`s vision for establishing a framework for trust on the
Internet,” said Peter Tippett, vice president of security solutions and
enterprise innovation at Verizon Business. “As a founding member of OIX, Verizon
is working with other key Internet players to push for industry-wide reform that
will forever change the way consumers and businesses interact on the Internet.”

“Trust, privacy and security are critical to the safe adoption of an identity
based digital infrastructure. The formation of the Open Identity Exchange is an
important step forward in creating the necessary framework to establish these
criteria,” said Tim Brown, CA chief security architect and distinguished
engineer. “With the support of industry leading companies and the OpenID and
Information Card Foundations, our efforts will help solve the digital trust
problems that our governments and industry face.”

“With more people expecting to access services and information online, federal
agencies need an easier, more secure approach when interacting with the public,”
said Patrick Peck, Executive Vice President of Booz Allen Hamilton. “Trust
Frameworks can provide this solution for more than 20,000 federal websites
through streamlined registration and simplified logins, and we are excited about
supporting this public-private partnership to bring operational benefits to
service providers and better access to the citizens they support.”

Mike Teets from OCLC explains, “There is a surprising amount of valuable content
available online through libraries that many consumers are not even aware of.
Many states and national governments license a vast amount of resources for
their citizens, and these could be made even more readily accessible through
this initiative. OIX will put a key piece of the infrastructure puzzle in place
to help libraries further reduce barriers of access to content, which is what
OCLC is all about.”

“Digital trust should originate from the location where it naturally occurs, be
it my municipality to validate my residency, my professional affiliations, my
educational institutions, my family affiliations, my religious affiliations,
etc.,” said Hal Warren, President of the OpenID Society, a chapter of the OIDF.
“This requires a complex multi-faceted framework through which trusted claims
can be transmitted and validated. This is the objective of the OIX. ‘Simplicity
is complexity well done’.”

“We look forward to facilitating trusted transactions throughout the government
and eventually Internet channels,” said Thibeau. “True trust requires the
participation of a broad community so we are engaging industry, government,
legal and academia leaders in how best to resolve challenges in usability,
security and privacy.”

About the Open Identity Exchange

The Open Identity Exchange (OIX) is a neutral, non-profit, multi-channel
provider of certification trust frameworks for open identity technologies. OIX
was founded by grants from the OpenID and Information Card Foundations and
support from companies including Google, PayPal, Equifax, VeriSign, Verizon, CA,
and Booz Allen Hamilton. It also includes non-profit members such as OCLC and
the OpenID Society.

for Open Identity Exchange (OIX)
Liz O`Donnell, 617-365-7172
pr@openidentityexchange.org

Copyright Business Wire 2010

Screen tests to predict future asthma attacks not effective for certain patients

Washington, September 1 (ANI): Scientists at UT Southwestern Medical Center say that certain clinical finding and lab tests, thought to have the potential to predict future asthma attacks, may be little successful when applied to people with persistent disease who are adhering to their health care regimens.

While previous reports have suggested that such screen tests can prove very helpful in predicting future asthma attacks, the researchers point out that the earlier conclusions were based on observations of patients with poorly controlled asthma who had not received care based on current guidelines.

“It was surprising to find that factors often used to predict future asthma risk in poorly treated populations were of no clinical benefit when applied to a well-treated, highly adherent population of inner-city adolescents and young adults with persistent asthma,” said Dr. Rebecca Gruchalla, chief of allergy and immunology at UT Southwestern.

The study involved 546 adolescents and young adults between the ages of 12 and 20 with persistent asthma, from 10 cities across the US.

The patients received care based on National Institutes of Health (NIH) guidelines for 46 weeks, and adhered to the treatment regime.

Despite the large number of disease characteristics examined, none was found to be particularly useful in predicting future disease activity.

To evaluate patient characteristics that best predicted future asthma symptoms and exacerbations, the researchers looked at traditional measurements of disease activity, such as frequency of asthma symptoms and lung function, as well as various markers of inflammation and allergic hypersensitivity.

“These findings highlight the need for us to identify better clinical predictors of asthma morbidity in patients who are both well-treated and who are compliant with their treatment regimes,” said Dr. Gruchalla.

A research article describing the study has been published in the Journal of Allergy and Clinical Immunology. (ANI)

Gene that suppresses skin cancer growth identified

London, March 30 (ANI): Scientists at the National Institutes of Health (NIH) in the U.S. have announced the discovery of a gene that suppresses tumour growth in melanoma, the deadliest form of skin cancer.

The finding was made as part of a systematic genetic analysis of a group of enzymes implicated in skin cancer, and many other types of cancer.

According to the analysis, one-quarter of human skin cancer tumours had mutations in genes that code for matrix metalloproteinase (MMP) enzymes.

The researchers believe that their findings may pave the way for more individualized cancer treatment strategies, where MMP and other key enzymes play a functional role in tumour growth and spread of the disease.

They even say that their study may help understand why drugs designed to treat cancer by blocking MMP enzymes have not been very successful as yet.

During the current study, the team led by researchers from the National Human Genome Research Institute (NHGRI) have found that MMP-8 actually serves as a tumour suppressor gene in melanoma, which is why may not be wise to block all MMPs in skin cancer patients with mutation in this gene.

The researchers say that a better approach may be to look for drugs that restore or increase MMP-8 function, or for drugs that block only those MMPs that are truly oncogenes-genes that encode proteins involved in normal cell growth.

“This research is an illustrative proof of concept that shows the value of genomic strategies for understanding cancer and possible therapies,” Nature magazine quoted Dr. Eric Green, NHGRI Scientific Director, as saying.

“It is gratifying to see that genomic technologies are guiding scientific discovery, advancing cancer research, especially melanoma research,” Green added.

While experimenting on mice, the researcher observed that when they injected the animals with cells expressing normal MMP-8, they would not develop skin ulcers.

However, when the mice were injected with cells expressing mutated MMP-8, they went on to develop ulcerations and metastases in their lungs.

A research article on the gene discovery has been published in the journal Nature Genetics. (ANI)

Heart-healthy, low-cal diets promote weight loss

London, Feb 26 (ANI): A new study has suggested that heart-healthy diets that reduce calorie intake – regardless of differing proportions of fat, protein, or carbohydrate – can help overweight and obese adults achieve and maintain weight loss.

During the study, researchers found similar weight loss after six months and two years among participants assigned to four diets that differed in their proportions of these three major nutrients.

The diets were low or high in total fat (20 or 40 percent of calories) with average or high protein (15 or 25 percent of calories). Carbohydrate content ranged from 35 to 65 percent of calories.

The diets all used the same calorie reduction goals and were heart-healthy-low in saturated fat and cholesterol while high in dietary fiber.

Researchers found that on average, participants lost 13 pounds at six months and maintained a 9-pound loss at two years.

They also found that participants reduced their waistlines by 1 to 3 inches by the end of the study. Craving, fullness, hunger, and diet satisfaction were all similar across the four diets.

“These results show that, as long as people follow a heart-healthy, reduced-calorie diet, there is more than one nutritional approach to achieving and maintaining a healthy weight,” said Elizabeth G. Nabel, M.D., director, National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).

“This provides people who need to lose weight with the flexibility to choose an approach that they’re most likely to sustain-one that is most suited to their personal preferences and health needs,” she added.

Research was conducted in Boston at Harvard University School of Public Health and at the Pennington Biomedical Research Center of Louisiana State University in Baton Rouge, La

The study has been published in the New England Journal of Medicine. (ANI)

Brain stimulation via mild electrical current may enhance motor skill learning

Washington, January 20 (ANI): A new study conducted by researchers at the National Institutes of Health (NIH) suggests that mild electrical current may prove very helpful in rehabilitating people with traumatic brain injury, stroke, and other conditions.

Revealing the observations made during the study in the Proceedings of the National Academy of Sciences, the researchers said that people who had received a mild electrical current to a motor control area of the brain were significantly better able to learn and perform a complex motor task than those in control groups.

Motor skills, which are used for activities from typing and driving, to sports, require practice and learning over a prolonged period of time.

During practice, the brain encodes information about how to perform the task, but even during periods of rest, the brain is still at work strengthening the memory of doing the task. This process is known as consolidation.

Working in collaboration with scientists from Columbia University in New York City and Johns Hopkins University in Baltimore, the research team from NIH’s National Institute of Neurological Disorders and Stroke (NINDS) presented the study subjects with a novel and challenging motor task, which involved squeezing a “joy stick” to play a targeting game on a computer monitor, which they practiced over five consecutive days.

One group received 20 minutes of transcranial direct current stimulation (tDCS) while practising, but the other group received only a 30 second “sham” stimulation.

The stimulation process involved mild electrical stimulation applied through surface electrodes on the head, and worked by modulating the activity of cells in the brain’s outermost layers.

Dr. Leonardo Cohen, of NINDS Human Cortical Physiology and Stroke Neurorehabilitation Section, revealed that his team directed tDCS to the primary motor cortex, the part of the brain that controls movement.

He and his colleagues observed that over the five-day training period, the skill of the tDCS group improved significantly more than those of the control group, apparently through an effect on consolidation.

During the three-month follow-up period, the two groups forgot the skill at about the same rate, but the tDCS group continued to perform better because they had learnt the skill better by the end of training. (ANI)